[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled.
 
 
ijms-logo

Journal Browser

Journal Browser

Stress-Related Disorders and Depression: From Molecular Basis to Therapy (2nd Edition)

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".

Deadline for manuscript submissions: 20 June 2025 | Viewed by 9647

Special Issue Editors


E-Mail Website
Guest Editor
Department of Brain Biochemistry, Maj Institute of Pharmacology of the Polish Academy of Sciences, Smętna 12, 31-343 Krakow, Poland
Interests: neuroscience; neuropharmacology; stress-related disorders; depression; psychotropic drugs; GPCR signaling; noradrenergic system; neuroplasticity, neuroimmune interaction
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Stress is defined as a challenge to the homeostasis of an organism by events coming from the environment. Two major systems are essential in the response to stressors: the sympathetic adrenomedullary system and the hypothalamic–pituitary–adrenal axis (HPA). Elevated by stress, noradrenaline and HPA axis-related hormones (including CRH, vasopressin, ACTH, corticosteroids) influence the gene transcription processes and the functioning of neurotransmitter systems. The immune system’s responsiveness is also affected. Via alterations to brain structure, chemistry, and function, chronic stress contributes to depression and various anxiety disorders, including posttraumatic stress disorder (PTSD). There is evidence demonstrating that chronic stress may also contribute to addiction and obesity.

The purpose of this Special Issue is to collect original research articles and review papers that concern the study of how the brain transduces environmental stress exposure into depression and stress-related diseases. We aim to bring together the most recent studies and use different experimental approaches, in vivo or in vitro, for the purpose of addressing:

  1. molecular and cellular responses to stress;
  2. stress-induced changes in the neurochemical cross-talk between signaling systems in the brain;
  3. methods to study the effects of various stressors in psychiatric disease models;
  4. stress vulnerability and resilience;
  5. stress biomarkers;
  6. therapies for stress-related disorders.

Prof. Dr. Irena Nalepa
Dr. Agnieszka Zelek-Molik
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • psychobiology of stress
  • depression
  • posttraumatic stress disorder
  • anxiety disorders
  • animal models
  • biogenic monoamines
  • glucocorticoids
  • inflammation
  • antidepressant and anxiolytic drugs

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (6 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 10646 KiB  
Article
Neuronal TCF7L2 in Lateral Habenula Is Involved in Stress-Induced Depression
by Xincheng Li, Xiaoyu Liu, Jiaxin Liu, Fei Zhou, Yunluo Li, Ye Zhao, Xueyong Yin, Yun Shi and Haishui Shi
Int. J. Mol. Sci. 2024, 25(22), 12404; https://doi.org/10.3390/ijms252212404 - 19 Nov 2024
Viewed by 632
Abstract
Depression is a complex psychiatric disorder that has substantial implications for public health. The lateral habenula (LHb), a vital brain structure involved in mood regulation, and the N-methyl-D-aspartate receptor (NMDAR) within this structure are known to be associated with depressive behaviors. Recent research [...] Read more.
Depression is a complex psychiatric disorder that has substantial implications for public health. The lateral habenula (LHb), a vital brain structure involved in mood regulation, and the N-methyl-D-aspartate receptor (NMDAR) within this structure are known to be associated with depressive behaviors. Recent research has identified transcription factor 7-like 2 (TCF7L2) as a crucial transcription factor in the Wnt signaling pathway, influencing diverse neuropsychiatric processes. In this study, we explore the role of TCF7L2 in the LHb and its effect on depressive-like behaviors in mice. By using behavioral tests, AAV-mediated gene knockdown or overexpression, and pharmacological interventions, we investigated the effects of alterations in TCF7L2 expression in the LHb. Our results indicate that TCF7L2 expression is reduced in neurons within the LHb of male ICR mice exposed to chronic mild stress (CMS), and neuron-specific knockdown of TCF7L2 in LHb neurons leads to notable antidepressant activity, as evidenced by reduced immobility time in the tail suspension test (TST) and forced swimming test (FST). Conversely, the overexpression of TCF7L2 in LHb neurons induces depressive behaviors. Furthermore, the administration of the NMDAR agonist NMDA reversed the antidepressant activity of TCF7L2 knockdown, and the NMDAR antagonist memantine alleviated the depressive behaviors induced by TCF7L2 overexpression, indicating the involvement of NMDAR. These findings offer novel insights into the molecular mechanisms of depression, highlighting the potential of TCF7L2 as both a biomarker and a therapeutic target for depression. Exploring the relationship between TCF7L2 signaling and LHb function may lead to innovative therapeutic approaches for alleviating depressive symptoms. Full article
Show Figures

Figure 1

Figure 1
<p>TCF7L2 in LHb neurons was downregulated in CMS mice. (<b>A</b>) Timeline of the CMS and behavioral tests, including the OFT, the TST, the EPM, the FST, and the SPT. (<b>B</b>) Time spent in the center in the OFT, mean of Naive: 30.98, mean of CMS: 18.46. (<b>C</b>) Total distance traveled during the OFT, mean of Naive: 2773, mean of CMS: 3258. (<b>D</b>) Latency to the first immobility in the TST, mean of Naive: 108.07, mean of CMS: 106.71. (<b>E</b>) Total immobility time in the TST, mean of Naive: 51.2, mean of CMS: 138.1. (<b>F</b>) Time spent in the open arms in the EPM, mean of Naive: 54.63, mean of CMS: 42.79. (<b>G</b>) Latency to the first floating in the FST, mean of Naive: 96.36, mean of CMS: 85.21. (<b>H</b>) Total floating time in the FST, mean of Naive: 93, mean of CMS: 139.9. (<b>I</b>) Sucrose preference (%) of SPT, mean of Naive: 75.69, mean of CMS: 61.18, (<b>J</b>,<b>K</b>) Immunofluorescence staining of TCF7L2 in LHb neurons, mean of Naive: 37.34, mean of CMS: 17.47, (red: TCF7L2, green: NeuN, blue: DAPI, scale bar = 50 μm; n = 4). Comparison between the Naive and CMS groups was conducted using T-tests or Mann–Whitney U-tests. Data are expressed as means ± SEM. n = 14 per group. * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, *** <span class="html-italic">p</span> &lt; 0.001, versus the Naive group.</p>
Full article ">Figure 2
<p>TCF7L2 knockdown in the LHb neurons caused antidepressant activity in mice. (<b>A</b>) Schematic of the experimental design of AAV-mediated TCF7L2 knockdown in the LHb neurons of mice. (<b>B</b>) Verification of TCF7L2 knockdown efficiency using fluorescence staining, mean of AAV-sh-scrambled: 93, mean of AAV-sh-TCF7L2: 139.9 (red: TCF7L2, green: GFP, blue: DAPI, scale bar = 50 μm). (<b>C</b>) Sucrose preference (%) of SPT, mean of AAV-sh-scrambled: 67.24, mean of AAV-sh-TCF7L2: 62.92. (<b>D</b>) Latency to eat in the NSF test, mean of AAV-sh-scrambled: 45.1, mean of AAV-sh-TCF7L2: 19.5. (<b>E</b>) Total intake of food in the NSF test, mean of AAV-sh-scrambled: 0.3667, mean of AAV-sh-TCF7L2: 0.3625. (<b>F</b>) Latency to the first immobility in the TST, mean of AAV-sh-scrambled: 107.2, mean of AAV-sh-TCF7L2: 116.5. (<b>G</b>) Total immobility time in the TST, mean of AAV-sh-scrambled: 66.86, mean of AAV-sh-TCF7L2: 37.53. (<b>H</b>) Latency to the first floating in the FST, mean of AAV-sh-scrambled: 59, mean of AAV-sh-TCF7L2: 104.8. (<b>I</b>) Total floating time in the FST, mean of AAV-sh-scrambled: 125.9, mean of AAV-sh-TCF7L2: 32.81. (<b>J</b>) Time spent in the center in the OFT, mean of AAV-sh-scrambled: 17.17, mean of AAV-sh-TCF7L2: 15.25. (<b>K</b>) Total distance traveled during the OFT, mean of AAV-sh-scrambled: 4039, mean of AAV-sh-TCF7L2: 3870. (<b>L</b>) Recognition index of NOR test, mean of AAV-sh-scrambled: 66.21, mean of AAV-sh-TCF7L2: 62.33. (<b>M</b>) Sniffing index in trial 1 of the three-chamber SIT, mean of AAV-sh-scrambled: 75.78, mean of AAV-sh-TCF7L2: 76.87. (<b>N</b>) Total sniffing time in trial 1 of the three-chamber SIT, mean of AAV-sh-scrambled: 85.82, mean of AAV-sh-TCF7L2: 77.41. (<b>O</b>) Preference index in trial 2 of the three-chamber SIT, mean of AAV-sh-scrambled: 35.31, mean of AAV-sh-TCF7L2: 35.61. (<b>P</b>) Total sniffing time in trial 2 of the three-chamber SIT, mean of AAV-sh-scrambled: 67.45, mean of AAV-sh-TCF7L2: 64.59. (<b>Q</b>) Analysis of the correlation between the total floating time in FST and density of TCF7L2<sup>+</sup> cells in LHb/mm<sup>2</sup>. Comparison between the AAV-sh-Scrambled and AAV-sh-TCF7L2 groups was conducted using the <span class="html-italic">T</span>-test or Mann–Whitney U-test. Data are expressed as means ± SEM. n = 10–23 per group. * <span class="html-italic">p</span> &lt; 0.05, *** <span class="html-italic">p</span> &lt; 0.001, versus the AAV-sh-Scrambled group.</p>
Full article ">Figure 3
<p>TCF7L2 overexpression in the LHb neurons led to depressive-like behavior in mice. (<b>A</b>) Schematic of the experimental design of AAV-mediated TCF7L2 overexpression in the LHb neurons of mice. (<b>B</b>) Verification of AAV injection point using fluorescence staining, mean of AAV-EGFP: 67.45, mean of AAV-TCF7L2: 64.59 (red: TCF7L2, green: GFP, blue: DAPI, scale bar = 50 μm). (<b>C</b>) Sucrose preference (%) of SPT, mean of AAV-EGFP: 73.5, mean of AAV-TCF7L2: 74. (<b>D</b>) Latency to eat in the NSF test, mean of AAV-EGFP: 45.33, mean of AAV-TCF7L2: 124.27. (<b>E</b>) Total intake of food in the NSF test, mean of AAV-EGFP: 0.22, mean of AAV-TCF7L2: 0.16. (<b>F</b>) Latency to the first immobility in the TST, mean of AAV-EGFP: 97, mean of AAV-TCF7L2:88.06. (<b>G</b>) Total immobility time in the TST, mean of AAV-EGFP: 60.39, mean of AAV-TCF7L2: 98.89. (<b>H</b>) Latency to the first floating in the FST, mean of AAV-EGFP: 87.67, mean of AAV-TCF7L2: 64.11. (<b>I</b>) Total floating time in the FST, mean of AAV-EGFP: 50.06, mean of AAV-TCF7L2: 117.4. (<b>J</b>) Time spent in the center in the OFT, mean of AAV-EGFP: 17.61, mean of AAV-TCF7L2: 17.9. (<b>K</b>) Total distance traveled during the OFT, mean of AAV-EGFP: 2235, mean of AAV-TCF7L2: 2147. (<b>L</b>) Recognition index of NOR test, mean of AAV-EGFP: 59.34, mean of AAV-TCF7L2: 62.5. (<b>M</b>) Sniffing index in trial 1 of the three-chamber SIT, mean of AAV-EGFP: 79.49, mean of AAV-TCF7L2: 82.19. (<b>N</b>) Total sniffing time in trial 1 of the three-chamber SIT, mean of AAV-EGFP: 75.94, mean of AAV-TCF7L2: 78.22. (<b>O</b>) Preference index in trial 2 of the three-chamber SIT, mean of AAV-EGFP: 29.86, mean of AAV-TCF7L2: 25.55. (<b>P</b>) Total sniffing time in trial 2 of the three-chamber SIT, mean of AAV-EGFP: 71.94, mean of AAV-TCF7L2: 76.83. Comparison between the AAV-EGFP and AAV-TCF7L2 groups was conducted using <span class="html-italic">T</span>-test or Mann–Whitney U-test. (<b>Q</b>) Analysis of the correlation between the total floating time in FST and density of TCF7L2<sup>+</sup> cells in LHb/mm<sup>2</sup>. Data are expressed as means ± SEM. n = 18 per group. * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, *** <span class="html-italic">p</span> &lt; 0.001, versus the AAV-sh-Scrambled group.</p>
Full article ">Figure 4
<p>NMDAR was involved in TCF7L2-mediated depressive-like behavior. (<b>A</b>) Experimental timeline for NMDAR agonist-NMDA administration and behavioral tests. (<b>B</b>) Effects of NMDA administration on latency to the first immobility in the TST with LHb neurons special TCF7L2 knockdown, mean of AAV-sh-scrambled + Saline: 106, mean of AAV-sh-scrambled + NMDA: 111.9, mean of AAV-sh-TCF7L2 + Saline: 111.1, mean of AAV-sh-TCF7L2 + NMDA: 108.8. (<b>C</b>) Total immobility time in the TST, mean of AAV-sh-scrambled + Saline: 57.75, mean of AAV-sh-scrambled + NMDA: 52.45, mean of AAV-sh-TCF7L2 + Saline: 8.143, mean of AAV-sh-TCF7L2 + NMDA: 62.63. (<b>D</b>) Effects of NMDA administration on latency to the first floating in the FST, mean of AAV-sh-scrambled + Saline: 72.36, mean of AAV-sh-scrambled + NMDA: 95.45, mean of AAV-sh-TCF7L2 + Saline: 110.9, mean of AAV-sh-TCF7L2 + NMDA: 102.6. (<b>E</b>) Total floating time in the FST, mean of AAV-sh-scrambled + Saline: 106.1, mean of AAV-sh-scrambled + NMDA: 120.7, mean of AAV-sh-TCF7L2 + Saline: 45, mean of AAV-sh-TCF7L2 + NMDA: 134.7. (<b>F</b>) Experimental timeline for NMDAR antagonist-memantine administration and behavioral tests. (<b>G</b>) Effects of memantine administration on latency to the first immobility in the TST with LHb neurons special TCF7L2 overexpression, mean of AAV-EGFP + Saline: 85.25, mean of AAV-EGFP + Memantine: 88.25, mean of AAV-TCF7L2 + Saline: 50.75, mean of AAV-TCF7L2 + Memantine: 80.05. (<b>H</b>) Total immobility time in the TST, mean of AAV-EGFP + Saline: 79.75, mean of AAV-EGFP + Memantine: 75.38, mean of AAV-TCF7L2 + Saline: 131.5, mean of AAV-TCF7L2 + Memantine: 72.38. (<b>I</b>) Effects of memantine administration on latency to the first floating in the FST, mean of AAV-EGFP + Saline: 91.5, mean of AAV-EGFP + Memantine: 100.8, mean of AAV-TCF7L2 + Saline: 35, mean of AAV-TCF7L2 + Memantine: 82.5. (<b>J</b>) Total floating time in the FST, mean of AAV-EGFP + Saline: 32.25, mean of AAV-EGFP + Memantine: 44.63, mean of AAV-TCF7L2 + Saline: 157.5, mean of AAV-TCF7L2 + Memantine: 77.88. Comparisons between groups were conducted using one-way ANOVA. Data are expressed as means ± SEM. n = 7–11 per group. * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, *** <span class="html-italic">p</span> &lt; 0.001.</p>
Full article ">
11 pages, 505 KiB  
Article
Relationship Between the Occurrence of Depression and DROSHA (rs6877842, rs10719) and XPO5 (rs11077) Single-Nucleotide Polymorphisms in the Polish Population: A Case–Control Study
by Mateusz Kowalczyk, Edward Kowalczyk, Monika Talarowska, Ireneusz Majsterek, Maciej Skrzypek, Tomasz Popławski, Monika Sienkiewicz, Anna Wiktorowska-Owczarek, Paulina Sokołowska and Marta Jóźwiak-Bębenista
Int. J. Mol. Sci. 2024, 25(22), 12204; https://doi.org/10.3390/ijms252212204 - 14 Nov 2024
Viewed by 780
Abstract
Although the epidemiology and symptoms of major depressive disorder (MDD) have been well-documented, the etiology and pathophysiology of the disease have not yet been fully explained. Depression arises from intricate interplay among social, psychological, and biological factors. Recently, there has been growing focus [...] Read more.
Although the epidemiology and symptoms of major depressive disorder (MDD) have been well-documented, the etiology and pathophysiology of the disease have not yet been fully explained. Depression arises from intricate interplay among social, psychological, and biological factors. Recently, there has been growing focus on the involvement of miRNAs in depression, with suggestions that abnormal miRNA processing locally at the synapse contributes to MDD. Changes in miRNAs may result from altered expression and/or function of the miRNA biogenesis machinery at the synapse. The aim of our research was to assess the relationship between the occurrence of depression and single-nucleotide polymorphisms (SNP) in the following genes in the Polish population: DROSHA (rs6877842; rs10719) and XPO5 (rs11077). This study involved 200 individuals, including 100 with depressive disorders in the study group (SG) and 100 healthy people without MDD in the control group (CG). All participants were unrelated native Caucasian Poles from central Poland. Blood samples were collected to evaluate the single-nucleotide polymorphism of the genes. Findings indicated that within our patient cohort, the risk of depression is increased by polymorphic variants of the rs10719/DROSHA and rs11077/XPO5 genes and lowered by rs6877842/DROSHA. Our study sheds light on the understanding of the genetic basis of depression, which can be used in the rapid diagnosis of this disease. Full article
Show Figures

Figure 1

Figure 1
<p>Link between SNPs in <span class="html-italic">DROSHA</span> and <span class="html-italic">XPO5</span> genes, their impact on miRNA biogenesis, neurogenesis, and synaptic plasticity and the associated risk of depression. ↑ increase; ↓ decrease.</p>
Full article ">
16 pages, 4753 KiB  
Article
Single Intranasal Administration of Ucn3 Affects the Development of PTSD Symptoms in an Animal Model
by Andrej Tillinger, Alexandra Zvozilová, Mojmír Mach, Ľubica Horváthová, Lila Dziewiczová and Jana Osacká
Int. J. Mol. Sci. 2024, 25(22), 11908; https://doi.org/10.3390/ijms252211908 - 6 Nov 2024
Viewed by 573
Abstract
Post-traumatic stress disorder (PTSD) is a multifactorial psychological disorder that affects different neurotransmitter systems, including the central CRH system. CRH acts via the CRHR1 and CRHR2 receptors, which exert opposite effects, i.e., anxiogenic or anxiolytic. The aim of this work was to investigate [...] Read more.
Post-traumatic stress disorder (PTSD) is a multifactorial psychological disorder that affects different neurotransmitter systems, including the central CRH system. CRH acts via the CRHR1 and CRHR2 receptors, which exert opposite effects, i.e., anxiogenic or anxiolytic. The aim of this work was to investigate how intranasal administration of the CRHR2-specific agonist urocortin 2 (Ucn2) or urocortin 3 (Ucn3) affects manifestations of PTSD in a single prolonged stress (SPS) animal model of PTSD. Elevated plus maze (EPM) and open field (OF) tests were used to assess anxiety-like behavior. Changes in the gene expressions of CRH, CRHR1, CRHR2, glucocorticoid receptor (GR), and FKBP5 were measured in brain regions (BNST, amygdala, and PVN) responsible for modulating the stress response. The SPS animals spent less time in the OF central zone and were less mobile than the controls; however, the Ucn3 treatment reversed this effect. SPS decreased the GR and FKPB5 mRNA levels in the PVN. Ucn3 suppressed the effect of SPS on FKBP5 mRNA expression in the PVN and increased FKBP5 mRNA in the BNST and PVN compared to the stressed animals. We demonstrate that Ucn3 has the potential to ameliorate anxiety-like behavior in SPS animals and also to affect the neuroendocrine system in the BNST and PVN. In addition, we confirm the important role of CRHR2 signaling in mediating the stress response. Full article
Show Figures

Figure 1

Figure 1
<p>The effects of intranasal CRHR2 agonist administration on anxiety-like behavior. The results of the elevated plus maze (EPM) behavioral measurements in the open arm (OA; (<b>A</b>–<b>D</b>)) and in the closed arm (CA; (<b>E</b>–<b>H</b>)). The data are presented as averages of the experimental group (mean ± SEM, <span class="html-italic">n</span> = 14 animals per group).</p>
Full article ">Figure 2
<p>The effects of intranasal CRHR2 agonist administration on anxiety-like behavior. The results of the open field (OF) behavioral measurements in the peripheral zone (PZ; (<b>A</b>–<b>C</b>)) and in the central zone (CZ; (<b>D</b>–<b>F</b>)). The data are presented as averages of the experimental group (mean ± SEM, <span class="html-italic">n</span> = 14 animals per group). * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01.</p>
Full article ">Figure 3
<p>The effects of the intranasal administration of CRHR2 agonists on corticosterone (CORT) plasmatic levels. The data are presented as averages of the experimental group (mean ± SEM, <span class="html-italic">n</span> = 9–10 animals per group).</p>
Full article ">Figure 4
<p>Changes in the gene expressions of <span class="html-italic">CRH</span> (<b>A</b>,<b>D</b>,<b>G</b>), <span class="html-italic">CRHR1</span> (<b>B</b>,<b>E</b>,<b>H</b>), and <span class="html-italic">CRHR2</span> (<b>C</b>,<b>F</b>,<b>I</b>) in selected brain regions involved in stress response mechanisms (BNST, Amy, and PVN). The data are presented as the fold changes relative to the control, taken as 1 (mean ± SEM, <span class="html-italic">n</span> = 8–10 animals per group). <span class="html-italic">t</span>-test: * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, *** <span class="html-italic">p</span> &lt; 0.001 vs. control, ## <span class="html-italic">p</span> &lt; 0.01 SPS vs. SPS + Ucn2.</p>
Full article ">Figure 5
<p>Changes in the gene expressions of the glucocorticoid receptor (<span class="html-italic">GR</span>; (<b>A</b>–<b>C</b>)) and <span class="html-italic">FKBP5</span> (<b>D</b>–<b>F</b>) in selected brain regions involved in stress response mechanisms (BNST, Amy, and PVN). The data are presented as fold changes relative to the control, taken as 1 (mean ± SEM, <span class="html-italic">n</span> = 8–10 animals per group). <span class="html-italic">t</span>-test: * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, *** <span class="html-italic">p</span> &lt; 0.001 vs. control, # <span class="html-italic">p</span> &lt; 0.05, ## <span class="html-italic">p</span> &lt; 0.01, ### <span class="html-italic">p</span> &lt; 0.001 vs. SPS + Ucn3.</p>
Full article ">Figure 6
<p>Representative images of immunofluorescence staining with anti-CRH in the PVN. 3V—3rd ventricle. White arrows indicate CRH-immunopositive neurons. Magnification ×200.</p>
Full article ">Figure 7
<p>Representative images of immunofluorescence staining with anti-pCREB in the brain regions involved in stress response mechanisms (PVN, Amy, and BNST). The table shows the number of pCREB-immunopositive cells in the ROI (region of interest). 3V—3rd ventricle, ac—anterior commissure, LV—lateral ventricle, opt—optic tract. <span class="html-italic">t</span>-test: * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, *** <span class="html-italic">p</span> &lt; 0.001 vs. control.</p>
Full article ">Figure 8
<p>A schematic illustration of the experimental design. The animals were randomly assigned to the four experimental groups which were as follows: control– non-stressed group with intranasal (IN) vehicle; SPS (single prolonged stress)—stressed group with IN vehicle; SPS + Ucn2—stressed group with IN Ucn2; SPS + Ucn3—stressed group with IN Ucn3. After SPS, the animals were left undisturbed in their cages for seven days to develop PTSD symptoms. After 7 days in the habituation period, the animals were tested in the elevated plus maze (EPM), and 48 h after the EPM, in the open field (OF). The animals were sacrificed 72 h after the OF test.</p>
Full article ">Figure 9
<p>Areas marked with a white circle represent the region of interest (ROI) for counting the pCREB-immunopositive cells. Magnification ×200.</p>
Full article ">
23 pages, 2417 KiB  
Article
Postpartum Oxytocin Treatment via the Mother Reprograms Long-Term Behavioral Disorders Induced by Early Life Stress on the Plasma and Brain Metabolome in the Rat
by Sara Morley-Fletcher, Alessandra Gaetano, Vance Gao, Eleonora Gatta, Gilles Van Camp, Hammou Bouwalerh, Pierre Thomas, Ferdinando Nicoletti and Stefania Maccari
Int. J. Mol. Sci. 2024, 25(5), 3014; https://doi.org/10.3390/ijms25053014 - 5 Mar 2024
Cited by 1 | Viewed by 1539
Abstract
The rat model of perinatal stress (PRS), in which exposure of pregnant dams to restraint stress reduces maternal behavior, is characterized by a metabolic profile that is reminiscent of the “metabolic syndrome”. We aimed to identify plasma metabolomic signatures linked to long-term programming [...] Read more.
The rat model of perinatal stress (PRS), in which exposure of pregnant dams to restraint stress reduces maternal behavior, is characterized by a metabolic profile that is reminiscent of the “metabolic syndrome”. We aimed to identify plasma metabolomic signatures linked to long-term programming induced by PRS in aged male rats. This study was conducted in the plasma and frontal cortex. We also investigated the reversal effect of postpartum carbetocin (Cbt) on these signatures, along with its impact on deficits in cognitive, social, and exploratory behavior. We found that PRS induced long-lasting changes in biomarkers of secondary bile acid metabolism in the plasma and glutathione metabolism in the frontal cortex. Cbt treatment demonstrated disease-dependent effects by reversing the metabolite alterations. The metabolomic signatures of PRS were associated with long-term cognitive and emotional alterations alongside endocrinological disturbances. Our findings represent the first evidence of how early life stress may alter the metabolomic profile in aged individuals, thereby increasing vulnerability to CNS disorders. This raises the intriguing prospect that the pharmacological activation of oxytocin receptors soon after delivery through the mother may rectify these alterations. Full article
Show Figures

Graphical abstract

Graphical abstract
Full article ">Figure 1
<p>Experimental timeline. Restraint stress was performed during the last 10 days of gestation. Dams were treated with carbetocin i.p. during the first seven days of lactation. This experiment included 4 different experimental groups for the progeny: the PRS group whose mothers were treated with carbetocin (PRS-Cbt) or vehicle (PRS-Veh) and the corresponding control unstressed groups (Cont-Cbt or Cont-Veh). Behavioral tests were performed during aging (17–22 mo). Tissues for endocrinological and metabolomic analyses were collected when animals were 22 months of age.</p>
Full article ">Figure 2
<p>Long-term alterations induced by PRS on behavior and metabolism and reversal by carbetocin. (<b>A</b>) Exploratory activity in the open field (n = 10–13 rats/group) represented as the time spent (%) in the corners and the center. (<b>B</b>) Social interaction (n = 9 rats/group) represented by sniffing activity (sec/5 min trial). (<b>C</b>) Spatial recognition memory in the Y-maze (n = 9–14 rats/group); the time spent (%) was the parameter analyzed. (<b>D</b>,<b>E</b>) Spatial learning on the Morris water maze (MWM) (n = 9–13 rats/group); the latency and distance to find the hidden platform, respectively. (<b>F</b>) Weight of the aged progeny at 17, 20, and 22 months (n = 8 rats/group). (<b>G</b>–<b>J</b>) Plasma levels of glucose (mg/dL) (n = 7–13 rats/group), insulin (ng/mL) (n = 6–11 rats/group), corticosterone (ng/mL) (n = 8–10 rats/group), and oxytocin (pg/mL) (n = 7–10 rats/group), respectively. (<b>K</b>) Pearson correlation between corticosterone and oxytocin levels (n = 6 rats/group). Values are expressed as means ± S.E.M. * indicates the PRS effect and # indicates the Cbt effect. Specifically, in the figure, PRS × Cbt interaction */# <span class="html-italic">p</span> &lt; 0.05; **/## <span class="html-italic">p</span> &lt; 0.01; ***/### <span class="html-italic">p</span> &lt; 0.001. PRS main effect * <span class="html-italic">p</span> &lt; 0.05; ** <span class="html-italic">p</span> &lt; 0.01; *** <span class="html-italic">p</span> &lt; 0.001; Cbt main effect # <span class="html-italic">p</span> &lt; 0.05; ## <span class="html-italic">p</span> &lt; 0.01; ### <span class="html-italic">p</span> &lt; 0.001.</p>
Full article ">Figure 3
<p>Metabolomic effect-size. Volcano plot and Euclidian distances of the plasma and brain metabolome. The dashed lines in the volcano plots represent the threshold of false discovery rate &lt; 0.2. The significance of the Euclidean distance between groups was calculated by PERMANOVA. (n = 6 rat/group).</p>
Full article ">Figure 4
<p>Long-term impact of PRS and carbetocin on bile acid metabolism in plasma. PRS elevated metabolites of bile acids’ specifically secondary acid pathways, and Carbetocin restored it to control unstressed levels. This table illustrates two-way ANOVA and ANOVA ratio contrasts for intergroup comparisons. Fold change values between groups are shown. In the two-way ANOVA, blue cells indicate a significant ANOVA effect <span class="html-italic">p</span> &lt; 0.05, and the light blue indicates that <span class="html-italic">p</span> narrowly missed the statistical cutoff for ANOVA significance, 0.05 &lt; <span class="html-italic">p</span> &lt; 0.10. In the ANOVA ratio contrast, red cells indicate a significant difference (<span class="html-italic">p</span> &lt; 0.05) between groups, with a metabolite ratio &gt; 1.00 (upregulation), while green cells indicate a significant difference for metabolite ratios &lt; 1.00 (downregulation). Box plots display the median value, upper quartile limit, and lower quartile limit. The solid bar across the box represents the median value of those measured, while + represents the mean. The following metabolites are included: 7-Hoca, beta-muricholate, and hyocholate (n = 6 rat/group).</p>
Full article ">Figure 5
<p>Long-term impact of PRS and carbetocin on glutathione metabolism in the brain prefrontal cortex. This table illustrates two-way ANOVA and ANOVA ratio contrasts for intergroup comparisons. Fold change values between groups are shown. In the two-way ANOVA, blue cells indicate a significant ANOVA effect <span class="html-italic">p</span> &lt; 0.05, and the light blue indicates that <span class="html-italic">p</span> narrowly missed the statistical cutoff for ANOVA significance, 0.05 &lt; <span class="html-italic">p</span> &lt; 0.10. In the ANOVA ratio contrast, red cells indicate a significant difference (<span class="html-italic">p</span> &lt; 0.05) between groups, with a metabolite ratio &gt; 1.00 (upregulation), while green cells indicate a significant difference for metabolite ratios &lt; 1.00 (downregulation). Box plots display the median value, upper quartile limit, and lower quartile limit. The solid bar across the box represents the median value of those measured, while + represents the mean. The following metabolites are included: cystine, cysteine-glutathione disulfide, and 5-oxoproline (n = 6 rat/group).</p>
Full article ">Figure 6
<p>Long-term impact of PRS and carbetocin on microbially derived sub-pathways in plasma and brain prefrontal cortex. This table illustrates two-way ANOVA and ANOVA ratio contrasts for intergroup comparisons. Fold change values between groups are shown. In the two-way ANOVA, blue cells indicate a significant ANOVA effect <span class="html-italic">p</span> &lt; 0.05, and the light blue indicates that <span class="html-italic">p</span> narrowly missed the statistical cutoff for ANOVA significance, 0.05 &lt; <span class="html-italic">p</span> &lt; 0.10. In the ANOVA ratio contrast, red cells indicate a significant difference (<span class="html-italic">p</span> &lt; 0.05) between groups, with a metabolite ratio &gt; 1.00 (upregulation), while green cells indicate a significant difference for metabolite ratios &lt; 1.00 (downregulation). Box plots display the median value, upper quartile limit, and lower quartile limit. The solid bar across the box represents the median value of those measured, while + represents the mean. The following metabolites are included: 3-(4-hydroxyphenyl)lactate, Hippurate, and indoleacetylglycine (n = 6 rat/group).</p>
Full article ">Figure 7
<p>Long-term impact of PRS and carbetocin on histidine (inflammation) derived sub-pathways in plasma and brain prefrontal cortex. This table illustrates two-way ANOVA and ANOVA ratio contrasts for intergroup comparisons. Fold change values between groups are shown. In the two-way ANOVA, blue cells indicate a significant ANOVA effect <span class="html-italic">p</span> &lt; 0.05, and the light blue indicates that <span class="html-italic">p</span> narrowly missed the statistical cutoff for ANOVA significance, 0.05 &lt; <span class="html-italic">p</span> &lt; 0.10. In the ANOVA ratio contrast, red cells indicate a significant difference (<span class="html-italic">p</span> &lt; 0.05) between groups, with a metabolite ratio &gt; 1.00 (upregulation), while green cells indicate a significant difference for metabolite ratios &lt; 1.00 (downregulation). Box plots display the median value, upper quartile limit, and lower quartile limit. The solid bar across the box represents the median value of those measured, while + represents the mean. The following metabolites are included: histidine, 1-methyl4-imidazoleacetate, 3-methyl-histidine, and imidazole propionate (n = 6 rat/group).</p>
Full article ">Figure 8
<p>Long-term impact of PRS and carbetocin on a urea cycle sub-pathway in the plasma and brain prefrontal cortex. This table illustrates two-way ANOVA and ANOVA ratio contrasts for intergroup comparisons. Fold change values between groups are shown. In the two-way ANOVA, blue cells indicate a significant ANOVA effect <span class="html-italic">p</span> &lt; 0.05, and the light blue indicates that <span class="html-italic">p</span> narrowly missed the statistical cutoff for ANOVA significance, 0.05 &lt; <span class="html-italic">p</span> &lt; 0.10. In the ANOVA ratio contrast, red cells indicate a significant difference (<span class="html-italic">p</span> &lt; 0.05) between groups, with a metabolite ratio &gt; 1.00 (upregulation), while green cells indicate a significant difference for metabolite ratios &lt; 1.00 (downregulation). Box plots display the median value, upper quartile limit, and lower quartile limit. The solid bar across the box represents the median value of those measured, while + represents the mean. The following metabolites are included: homoarginine and homocitrulline (n = 6 rat/group).</p>
Full article ">Figure 9
<p>Enrichment analysis in plasma and brain metabolome. Top-ranking HMDB ontology categories enriched for metabolites altered by PRS in the plasma and brain prefrontal cortex, as well as their reversal by Cbt.</p>
Full article ">

Review

Jump to: Research

22 pages, 1054 KiB  
Review
Bridging Neurobiological Insights and Clinical Biomarkers in Postpartum Depression: A Narrative Review
by Keyi Zhang, Lingxuan He, Zhuoen Li, Ruxuan Ding, Xiaojiao Han, Bingqing Chen, Guoxin Cao, Jiang-Hong Ye, Tian Li and Rao Fu
Int. J. Mol. Sci. 2024, 25(16), 8835; https://doi.org/10.3390/ijms25168835 - 14 Aug 2024
Viewed by 3407
Abstract
Postpartum depression (PPD) affects 174 million women worldwide and is characterized by profound sadness, anxiety, irritability, and debilitating fatigue, which disrupt maternal caregiving and the mother–infant relationship. Limited pharmacological interventions are currently available. Our understanding of the neurobiological pathophysiology of PPD remains incomplete, [...] Read more.
Postpartum depression (PPD) affects 174 million women worldwide and is characterized by profound sadness, anxiety, irritability, and debilitating fatigue, which disrupt maternal caregiving and the mother–infant relationship. Limited pharmacological interventions are currently available. Our understanding of the neurobiological pathophysiology of PPD remains incomplete, potentially hindering the development of novel treatment strategies. Recent hypotheses suggest that PPD is driven by a complex interplay of hormonal changes, neurotransmitter imbalances, inflammation, genetic factors, psychosocial stressors, and hypothalamic–pituitary–adrenal (HPA) axis dysregulation. This narrative review examines recent clinical studies on PPD within the past 15 years, emphasizing advancements in neuroimaging findings and blood biomarker detection. Additionally, we summarize recent laboratory work using animal models to mimic PPD, focusing on hormone withdrawal, HPA axis dysfunction, and perinatal stress theories. We also revisit neurobiological results from several brain regions associated with negative emotions, such as the amygdala, prefrontal cortex, hippocampus, and striatum. These insights aim to improve our understanding of PPD’s neurobiological mechanisms, guiding future research for better early detection, prevention, and personalized treatment strategies for women affected by PPD and their families. Full article
Show Figures

Figure 1

Figure 1
<p>Tryptophan metabolism in the brain. Tryptophan is mainly metabolized through the kynurenine pathway (95%) and less so through the serotonin pathway (&lt;5%). In the kynurenine pathway, tryptophan is converted to kynurenine by IDO (in the brain) or TDO (in other tissues). This pathway splits into two branches: the KMO branch, where KMO (primarily in microglia) produces 3HK, 3HAA, QUIN, and NAD+, and the KAT branch, where KAT (mainly in astrocytes) converts kynurenine to KYNA. KYNA is neuroprotective, while QUIN is neurotoxic, with distinct effects on brain function.</p>
Full article ">Figure 2
<p>Laboratory Animal models of PPD: (1) Hormone withdrawal models. Ovariectomized female rats were injected with a low dose of estradiol benzoate and a high dose of progesterone dissolved in sesame oil daily for 16 consecutive days. From day 17 to 23, the dose of estradiol was increased to mimic the levels observed in pregnancy. From day 24 to 27, which is considered the postpartum period, mice only received vehicle (sesame oil) daily. (2) Chronic corticosterone treatment model. Dams were injected with high CORT during the postpartum period (postpartum day 2–24). (3) Gestational stress model. Depression is induced by exposing pregnant female mice to gestational stress from days 10 to 20 during pregnancy. (4) The chronic social stress model. A novel male was placed in their home cage for 1 h each day from days 2 to 16 of lactation, resulting in depressive behaviors. (5) The repeated maternal separation model. Depression is induced by separating the mothers from their pups for periods that last 3–6 h daily during the first 1–3 weeks postpartum.</p>
Full article ">Figure 3
<p>This review provides a comprehensive examination of postpartum depression (PPD) across four aspects: (1) Basic information, including clinical characteristics, brain imaging, and biomarkers, to offer an initial understanding. (2) Biological mechanisms, detailing PPD pathology with an emphasis on serotonin and kynurenine pathways, where kynurenine branches into neuroprotective KYNA and neurotoxic QUIN. (3) Laboratory animal models focused on hormone manipulation and stress, with model variations. (4) Neuronal mechanisms, involving key brain regions such as the PFC, AMY, HIPP, and striatum. Abbreviations: fMRI: functional magnetic resonance imaging; PET-CT: positron emission tomography-computed tomography; MRS: magnetic resonance spectroscopy; OXT: oxytocin; KYNA: kynurenic acid; QUIN: quinolinic acid; Cort: corticosterone; PFC: prefrontal cortex; AMY: amygdala; HIPP: hippocampus.</p>
Full article ">
18 pages, 1456 KiB  
Review
(R)-(-)-Ketamine: The Promise of a Novel Treatment for Psychiatric and Neurological Disorders
by Hana Shafique, Julie C. Demers, Julia Biesiada, Lalit K. Golani, Rok Cerne, Jodi L. Smith, Marta Szostak and Jeffrey M. Witkin
Int. J. Mol. Sci. 2024, 25(12), 6804; https://doi.org/10.3390/ijms25126804 - 20 Jun 2024
Cited by 6 | Viewed by 1900
Abstract
NMDA receptor antagonists have potential for therapeutics in neurological and psychiatric diseases, including neurodegenerative diseases, epilepsy, traumatic brain injury, substance abuse disorder (SUD), and major depressive disorder (MDD). (S)-ketamine was the first of a novel class of antidepressants, rapid-acting antidepressants, to [...] Read more.
NMDA receptor antagonists have potential for therapeutics in neurological and psychiatric diseases, including neurodegenerative diseases, epilepsy, traumatic brain injury, substance abuse disorder (SUD), and major depressive disorder (MDD). (S)-ketamine was the first of a novel class of antidepressants, rapid-acting antidepressants, to be approved for medical use. The stereoisomer, (R)-ketamine (arketamine), is currently under development for treatment-resistant depression (TRD). The compound has demonstrated efficacy in multiple animal models. Two clinical studies disclosed efficacy in TRD and bipolar depression. A study by the drug sponsor recently failed to reach a priori clinical endpoints but post hoc analysis revealed efficacy. The clinical value of (R)-ketamine is supported by experimental data in humans and rodents, showing that it is less sedating, does not produce marked psychotomimetic or dissociative effects, has less abuse potential than (S)-ketamine, and produces efficacy in animal models of a range of neurological and psychiatric disorders. The mechanisms of action of the antidepressant effects of (R)-ketamine are hypothesized to be due to NMDA receptor antagonism and/or non-NMDA receptor mechanisms. We suggest that further clinical experimentation with (R)-ketamine will create novel and improved medicines for some of the neurological and psychiatric disorders that are underserved by current medications. Full article
Show Figures

Figure 1

Figure 1
<p>Structures of racemic ketamine and its (<span class="html-italic">R</span>)- and (<span class="html-italic">S</span>)-enantiomers.</p>
Full article ">Figure 2
<p>Effects of (<span class="html-italic">R</span>)-ketamine on overall withdrawal scores in rats undergoing naloxone-precipitated withdrawal from subchronic morphine. Each bar represents the mean + SEM of data from eight rats V: vehicle; Nal: naloxone; R-ket: R-ketamine; ** <span class="html-italic">p</span> &lt; 0.01, *** <span class="html-italic">p</span> &lt; 0.001 compared to mor + nal group by Newman–Keuls multiple comparison test. Figure is modified from [<a href="#B54-ijms-25-06804" class="html-bibr">54</a>] with permission.</p>
Full article ">Figure 3
<p>(<span class="html-italic">R</span>)-ketamine (10 and 20 mg/kg) blocks the conditioned place preference engendered by 5 mg/kg morphine. * <span class="html-italic">p</span> &lt; 0.05 compared to vehicle + morphine treatment by Dunnett’s test. Each bar represents the mean + SEM of data from 9 to 13 mice/group. Figure is modified from [<a href="#B54-ijms-25-06804" class="html-bibr">54</a>] with permission.</p>
Full article ">Figure 4
<p>Frequency-rate response curves for the effects of (<span class="html-italic">R</span>)-ketamine (<b>left panel</b>) or (<span class="html-italic">S</span>)-ketamine (<b>right panel</b>) in rats responding under a schedule of electrical stimulation of the medial forebrain bundle (intracranial self-stimulation). Values represent the mean normalized response rate (% of maximum control responding) across 10 frequency presentations (1.75–2.20 log/Hz) of 10 rats. Error bars are omitted for clarity. Significant differences compared to vehicle at the respective frequencies are denoted by asterisks (* <span class="html-italic">p</span> &lt; 0.05; **** <span class="html-italic">p</span> &lt; 0.0001; <span class="html-italic">N</span> = 10). Data are from [<a href="#B54-ijms-25-06804" class="html-bibr">54</a>] with permission.</p>
Full article ">Figure 5
<p>(<span class="html-italic">R</span>)-ketamine did not fully substitute for the training dose of (<span class="html-italic">S</span>)-ketamine in (<span class="html-italic">S</span>)-ketamine-trained rats. Ns for vehicle and (<span class="html-italic">S</span>)-ketamine were eight, whereas eight rats were tested with (<span class="html-italic">R</span>)-ketamine (17.5 mg/kg). Symbols: * <span class="html-italic">p</span> &lt; 0.05, *** <span class="html-italic">p</span> &lt; 0.001 vs. vehicle, ### <span class="html-italic">p</span> &lt; 0.001 vs. training dose of (<span class="html-italic">S</span>)-ketamine. Dotted lines represent 25 and 75% accuracy. Data are from [<a href="#B76-ijms-25-06804" class="html-bibr">76</a>] with permission.</p>
Full article ">Figure 6
<p>(<span class="html-italic">R</span>)-ketamine at 10 and 20 mg/kg does not induce a conditioned place preference when given alone (+vehicle). Each bar represents the mean + SEM of data from 10 mice/group. Veh: vehicle or saline; R-ket: (<span class="html-italic">R</span>)-ketamine. Data are from [<a href="#B54-ijms-25-06804" class="html-bibr">54</a>] with permission.</p>
Full article ">
Back to TopTop